S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
DIS   127.56 (+0.73%)
Log in
NASDAQ:UTHR

United Therapeutics Stock Forecast, Price & News

$122.10
+3.25 (+2.73 %)
(As of 10/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$119.34
Now: $122.10
$122.28
50-Day Range
$99.90
MA: $105.22
$119.17
52-Week Range
$75.58
Now: $122.10
$127.79
Volume588,400 shs
Average Volume518,016 shs
Market Capitalization$5.42 billion
P/E Ratio12.54
Dividend YieldN/A
Beta0.71
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Read More
United Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292
Employees920

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.45 billion
Book Value$63.36 per share

Profitability

Net Income$-104,500,000.00

Miscellaneous

Market Cap$5.42 billion
Next Earnings Date10/28/2020 (Confirmed)
OptionableOptionable
$122.10
+3.25 (+2.73 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

How has United Therapeutics' stock price been impacted by Coronavirus?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UTHR shares have increased by 29.9% and is now trading at $122.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of United Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for United Therapeutics
.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for United Therapeutics
.

How can I listen to United Therapeutics' earnings call?

United Therapeutics will be holding an earnings conference call on Wednesday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $2.41. The biotechnology company earned $362 million during the quarter, compared to the consensus estimate of $339.97 million. United Therapeutics had a net margin of 30.04% and a return on equity of 14.90%. The firm's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.63 EPS.
View United Therapeutics' earnings history
.

What price target have analysts set for UTHR?

8 brokers have issued 12 month price targets for United Therapeutics' shares. Their forecasts range from $80.00 to $244.00. On average, they anticipate United Therapeutics' stock price to reach $143.38 in the next year. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for United Therapeutics
.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Celgene (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 65, Pay $2.98M)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 48, Pay $1.8M)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 52, Pay $1.3M)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $1.53M)
  • Mr. Dewey Steadman C.F.A., CFA, Head of Investor Relations

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.58%), Retirement Systems of Alabama (0.13%), Greylin Investment Mangement Inc. (0.12%), Pacer Advisors Inc. (0.05%), Nisa Investment Advisors LLC (0.04%) and State of Alaska Department of Revenue (0.03%). Company insiders that own United Therapeutics stock include Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics
.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Greylin Investment Mangement Inc., Wedge Capital Management L L P NC, Assenagon Asset Management S.A., Nisa Investment Advisors LLC, Denali Advisors LLC, Campbell & CO Investment Adviser LLC, Envestnet Asset Management Inc., and World Asset Management Inc. Company insiders that have sold United Therapeutics company stock in the last year include Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner, and Tommy G Thompson.
View insider buying and selling activity for United Therapeutics
.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Polianta Ltd, Regentatlantic Capital LLC, State of Alaska Department of Revenue, Retirement Systems of Alabama, Cardinal Capital Management, NEXT Financial Group Inc, and Crossmark Global Holdings Inc..
View insider buying and selling activity for United Therapeutics
.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $122.10.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.42 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. United Therapeutics employs 920 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.